🌱 created from: subsequent_therapies-of-hepatocellular_carcinoma

keynote-240

• Design: Phase III, multi-center, randomized, double-blind
• Number of patients: 413
• Patients characteristics: Advanced HCC, previously treated with sorafenib
• Agent: Pembrolizumab plus best supportive care vs. placebo plus BSC
• Treatment line: Previously treated with sorafenib
• Trial Acronym (if provided) or NCTId Number: NCT02702401
• Comparison of efficacy in one markdown table
• Highlight of toxicity:
  • Grade 3 or higher adverse events occurred in 52.7% of pembrolizumab patients vs. 46.3% of placebo patients,
  • with treatment-related adverse events in 18.6% vs. 7.5%, respectively
• One line summarize:
• Pembrolizumab showed improved overall survival and progression-free survival in previously treated advanced HCC patients, with manageable adverse events.